American journal of preventive cardiology最新文献

{"title":"Achievement of guideline-based lipid goals among very-high-risk patients with atherosclerotic cardiovascular disease and type 2 diabetes: results in 213,380 individuals from the cvMOBIUS2 registry","authors":"Satoshi Shoji ,&nbsp;Nishant P. Shah ,&nbsp;Peter Shrader ,&nbsp;Laine E. Thomas ,&nbsp;Jonathan D. Arnold ,&nbsp;Nafeesa N. Dhalwani ,&nbsp;Neena A. Thomas ,&nbsp;Bethany Kalich ,&nbsp;Elisa L. Priest ,&nbsp;Mahanaz Syed ,&nbsp;Cezary Wójcik ,&nbsp;Eric D. Peterson ,&nbsp;Ann Marie Navar","doi":"10.1016/j.ajpc.2024.100921","DOIUrl":"10.1016/j.ajpc.2024.100921","url":null,"abstract":"<div><h3>Objective</h3><div>Lowering lipid to reach guideline-indicated goals significantly reduces cardiovascular outcomes in very-high-risk (VHR) patients with atherosclerotic cardiovascular disease (ASCVD) and type 2 diabetes (DM2). How well VHR patients currently achieve these goals in community practice is unknown.</div></div><div><h3>Methods</h3><div>VHR patients with ASCVD and DM2 were identified across 14 US healthcare systems using electronic health records between 1/1/2021–12/31/2022. Achievement of guideline-based lipid goals was determined according to the 2018 AHA/ACC/Multisociety guideline, defined as either having a low-density lipoprotein-cholesterol &lt;70 mg/dL or receiving maximal lipid-lowering therapy (i.e., on a PCSK9i monoclonal antibody). Multivariable logistic regression was used to evaluate factors associated with the achievement of these goals.</div></div><div><h3>Results</h3><div>Among 213,380 eligible patients (median age 71.0 years, 42 % women), 51.8 % achieved guideline-based lipid goals. Female sex (odds ratio [OR], 0.64; 95 % confidence interval [CI], 0.61–0.66), Black race (OR, 0.67; 95 % CI, 0.63–0.72 vs white race), and those on Medicaid (OR, 0.92; 95 % CI, 0.86–0.97 vs Medicare) were associated with a lower likelihood of achieving guideline-based lipid goals. Overall, 76.0 % of patients were on statin, 40.5 % were on a high-intensity statin and only 5.8 % were on a statin in combination with ezetimibe or a PCSK9i monoclonal antibody.</div></div><div><h3>Conclusion</h3><div>Almost half of all VHR patients with ASCVD and DM2 do not achieve current guideline lipid goals. Women, Black individuals, and those on Medicaid were significantly less likely to achieve these goals relative to their counterparts. Further targeted quality improvement interventions are needed to improve the equitable achievement of guideline-based lipid goals.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"21 ","pages":"Article 100921"},"PeriodicalIF":4.3,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773273/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Abstracts from the ASPC 2024 congress on CVD prevention”","authors":"","doi":"10.1016/j.ajpc.2024.100898","DOIUrl":"10.1016/j.ajpc.2024.100898","url":null,"abstract":"","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"21 ","pages":"Article 100898"},"PeriodicalIF":4.3,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11731259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142985440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urinary albumin-to-creatinine ratio as an independent predictor of long-term mortality in atherosclerotic cardiovascular disease patients: A propensity score-matched study","authors":"Houyong Zhu ,&nbsp;Chao Yang ,&nbsp;Xiao Liu ,&nbsp;Xiaoqun Xu ,&nbsp;Qilan Chen ,&nbsp;Xiaojiang Fang ,&nbsp;Jinyu Huang ,&nbsp;Tielong Chen","doi":"10.1016/j.ajpc.2024.100920","DOIUrl":"10.1016/j.ajpc.2024.100920","url":null,"abstract":"<div><h3>Background and Aims</h3><div>Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of mortality, and while the association between the urinary albumin-to-creatinine ratio (UACR) and cardiovascular risk is recognized, the specific impact of UACR on the long-term survival of ASCVD patients remains not fully understood. The aim of this study is to investigate the influence of UACR on the long-term risk of all-cause mortality in patients with ASCVD.</div></div><div><h3>Methods</h3><div>This study included ASCVD patients from the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2018. Mortality outcomes were ascertained by linkage to the National Death Index as of December 31, 2019. UACR risk was stratified into three levels: Group 0 (UACR &lt; 30 mg/g), Group 1 (30–300 mg/g), and Group 2 (&gt;300 mg/g). The primary outcome was all-cause mortality, with cardiovascular mortality as a secondary outcome. Cox proportional hazards, adjusted for demographic factors, traditional cardiovascular risk factors, and secondary prevention medications for ASCVD, were used to analyze the cumulative risk of outcomes. Propensity score matching was employed for risk adjustment, and sensitivity analyses were conducted based on cohorts with chronic coronary syndrome (CCS), stroke, heart failure, and non-heart failure.</div></div><div><h3>Results</h3><div>Among the 1,737 patients with a median follow-up of 10 years, 1,026 all-cause deaths and 351 cardiovascular deaths were recorded. After full model adjustment, higher UACR levels were associated with increased risks of all-cause mortality (Group 1: hazard ratio (HR), 1.601; 95 % confidence interval (CI), 1.382–1.855; Group 2: HR, 2.378; 95 % CI, 1.884–3.001; both <em>P</em> &lt; 0.001 for trend) and cardiovascular mortality (Group 1: HR, 2.080; 95 % CI, 1.631–2.652; Group 2: HR, 2.883; 95 % CI, 1.951–4.260; both <em>P</em> &lt; 0.001 for trend). Propensity score matching confirmed these findings, showing significantly elevated all-cause mortality risks in high-risk UACR groups (with a cutoff of 30 mg/g: HR, 1.468 (95 %CI, 1.254–1.719), <em>P</em> &lt; 0.001; with a cutoff of 300 mg/g: HR, 1.935 (95 %CI, 1.399–2.675), <em>P</em> &lt; 0.001). All sensitivity analyses were consistent with the results of the overall cohort.</div></div><div><h3>Conclusion</h3><div>UACR is an important prognostic indicator for predicting the long-term outcomes of ASCVD patients, with its impact being independent of eGFR.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"21 ","pages":"Article 100920"},"PeriodicalIF":4.3,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11728069/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142980936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"American society for preventive cardiology 2024 cardiovascular disease prevention: Highlights and key sessions","authors":"Akhil A. Chandra ,&nbsp;Carlos Espiche ,&nbsp;Maisha Maliha ,&nbsp;Salim S Virani ,&nbsp;Roger S Blumenthal ,&nbsp;Fatima Rodriguez ,&nbsp;Nathan D Wong ,&nbsp;Martha Gulati ,&nbsp;Leandro Slipczuk ,&nbsp;Michael D Shapiro","doi":"10.1016/j.ajpc.2024.100919","DOIUrl":"10.1016/j.ajpc.2024.100919","url":null,"abstract":"<div><div>Groundbreaking strategies for preventive cardiology were showcased at the 2024 American Society for Preventive Cardiology (ASPC) Congress on Cardiovascular Disease (CVD) Prevention held in Salt Lake City, Utah, from August 2nd to 4th, 2024. The event featured 69 moderators and 13 scientific sessions comprised of 98 topics, 36 satellite events, 133 poster presentations, and 27 lifestyle classes.</div><div>The conference highlighted innovative strategies focused on integrating cardiovascular, kidney, and metabolic health, presenting a cohesive approach for managing complex, interrelated conditions. Pivotal studies have addressed the role of lipid-lowering therapies, the benefits of early statin initiation, and the importance of precision medicine in preventing CVD.</div><div>The ASPC's emphasis on translating this research into practical clinical tools has the potential to revolutionize preventive care strategies, making strides toward reducing the burden of CVD globally and improving long-term patient outcomes through personalized and early intervention approaches.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"21 ","pages":"Article 100919"},"PeriodicalIF":4.3,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11722599/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vascular ageing manifestations and hypertension in the community","authors":"Guillermo A. Alanis ,&nbsp;Pierre Boutouyrie ,&nbsp;Mouad Abouqateb ,&nbsp;Rosa Maria Bruno ,&nbsp;Rachel E. Climie ,&nbsp;Thomas van Sloten ,&nbsp;Nicolas Danchin ,&nbsp;Bruno Pannier ,&nbsp;Stéphane Laurent ,&nbsp;Xavier Jouven ,&nbsp;Jean-Philippe Empana","doi":"10.1016/j.ajpc.2024.100918","DOIUrl":"10.1016/j.ajpc.2024.100918","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the association between joint manifestations of vascular ageing (VA) and hypertension.</div></div><div><h3>Methods</h3><div>We used baseline (2008–2012) and follow-up data (up to 2024) from the Paris Prospective Study III, a French cohort of 10,157 participants. Prevalent and incident hypertension were determined at baseline (blood pressure ≥140/90 mmHg or on medication) and at 2, 4, 6, 8 and 10 years of follow-up (self-reported antihypertensive treatment). VA manifestations were assessed at baseline via echo-tracking in the right common carotid artery. Clustering analysis identified patterns of VA and their association with hypertension was assessed with logistic regression.</div></div><div><h3>Results</h3><div>The cross-sectional analysis included 9,096 participants (mean age: 59±6 years, 39 % female). Hypertension prevalence was 36 % (<em>n</em> = 3,276). Three clusters of VA manifestations were identified. Cluster 1 (<em>n</em> = 4,326;47.6 %) was characterized by healthy vascular ageing (HVA), Cluster 2 by increased arteriosclerosis (ART) (<em>n</em> = 2,274;25.0 %) and Cluster 3 by greater atherosclerosis prevalence (ATH) (<em>n</em> = 2,496;27.4 %). Compared to the HVA cluster, ART (aOR 3.94; 95 % CI 3.50;4.45) and ATH clusters (aOR 2.69; 95 % CI 2.38;3.04) were associated with prevalent hypertension. The prospective analysis included 5,310 normotensives with 754 (14.1 %) cases of incident hypertension (median follow-up of 10.05 years [range: 10.00;10.15]). Both ART (aOR 1.34; 95 % CI 1.08;1.65) and ATH (aOR 1.70; 95 % CI 1.40;2.07) clusters were associated with incident hypertension.</div></div><div><h3>Conclusion</h3><div>Vascular ageing manifestations reflecting increased carotid arteriosclerosis and atherosclerosis are related to prevalent and incident hypertension.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"21 ","pages":"Article 100918"},"PeriodicalIF":4.3,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11728902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142980937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Digital Health Interventions for the Optimization of Postpartum Cardiovascular Health: A Systematic Scoping Review","authors":"Anaïs Hausvater ,&nbsp;Mitchell Pleasure ,&nbsp;Dorice Vieira ,&nbsp;Darcy Banco ,&nbsp;John A. Dodson","doi":"10.1016/j.ajpc.2024.100917","DOIUrl":"10.1016/j.ajpc.2024.100917","url":null,"abstract":"<div><h3>Background</h3><div>Digital health technologies have been proposed as a potential solution to improving maternal cardiovascular (CV) health in the postpartum (PP) period. In this context we performed a systematic scoping review of digital health interventions designed to improve PP CV health.</div></div><div><h3>Methods</h3><div>We conducted a systematic review of PubMed/MEDLINE, EMBASE, CINAHL, Web of Science and the Cochrane Library. We included studies of PP women, with an intervention involving digital or mobile health (wearable devices, telemedicine, or remote monitoring). We included studies that measured an outcome related to CV health.</div></div><div><h3>Results</h3><div>110 full studies were reviewed for eligibility and 38 were included. Studies were categorized into 4 broad CV outcomes: blood pressure (BP), physical activity (PA), diet/weight loss and cardiometabolic markers. Digital health interventions included mobile applications, text-based coaching, interactive websites, virtual reality, wearable devices. The majority of remote BP monitoring programs (<em>N</em> = 5 studies) were successful in optimizing BP. 14 studies examined interventions aimed at improving PA levels of which 6/14 studies showed modest benefit at increasing PA. The majority of interventions aimed at weight loss (<em>N</em> = 27 studies) showed no significant benefit in terms of lowered caloric intake and/or weight loss up to 1 year PP. 6 studies examined improvements in cardiometabolic markers such as lipids and glucose levels, of which the majority showed no benefit.</div></div><div><h3>Conclusion</h3><div>The majority of studies we reviewed found that digital health interventions such as mobile health, telemonitoring and wearable devices were feasible and had mixed effectiveness in improving postpartum CV health in the postpartum period.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"21 ","pages":"Article 100917"},"PeriodicalIF":4.3,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11733190/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular health and risks of atrial fibrillation and its prognosis","authors":"Zuolin Lu ,&nbsp;Jiawen Ke ,&nbsp;Hongxi Yang ,&nbsp;Xiaoxuan Zhang ,&nbsp;Yachen Wang ,&nbsp;Yabing Hou ,&nbsp;Ruitai Shao","doi":"10.1016/j.ajpc.2024.100915","DOIUrl":"10.1016/j.ajpc.2024.100915","url":null,"abstract":"<div><h3>Background</h3><div>Atrial fibrillation (AF) is the most common cardiac arrhythmia around the world with an increased risk of a broad spectrum of adverse comorbidities and death. Whether cardiovascular health (CVH) is associated with AF development remains unclear.</div></div><div><h3>Methods</h3><div>238,420 participants without cardiovascular disease at baseline were selected from the UK Biobank study cohort from 2006 to 2010. CVH was defined based on “Life's Essential 8″ scores. Sex-specific multi-state Markov and flexible parametric survival models were used to estimate the hazard ratio (HR) and 95 % confidence intervals (95 % CI) for the associations of CVH with incident AF and its prognosis.</div></div><div><h3>Results</h3><div>In fully-adjusted models, CVH is significantly associated with a reduced risk of incident AF among both men and women, after accounting for the potential impact of death. Among AF patients without other evaluated diseases, a higher CVH score was generally linked with a reduced risk of death in both sexes. Among AF patients with incident prognostic diseases, only CVH associated with death following heart failure (0.78, 0.63–0.97) was observed among men, whereas CVH was significantly associated with death following coronary heart disease (0.80, 0.69–0.93), stroke (0.73, 0.61–0.89) and dementia (0.79, 0.71–1.03) among women.</div></div><div><h3>Conclusions</h3><div>We found significant associations between CVH and the risk reduction of incident AF and its prognostic outcomes, with these associations being more pronounced among women. Findings suggest a potential of screening CVH for both primary prevention of new-onset AF and the secondary prevention to improve AF prognosis.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"21 ","pages":"Article 100915"},"PeriodicalIF":4.3,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11728968/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142980935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipoprotein(a), high-sensitivity c-reactive protein, homocysteine and cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis","authors":"Sarah O. Nomura ,&nbsp;Harpreet S. Bhatia ,&nbsp;Parveen K. Garg ,&nbsp;Amy B. Karger ,&nbsp;Weihua Guan ,&nbsp;Jing Cao ,&nbsp;Michael D. Shapiro ,&nbsp;Michael Y. Tsai","doi":"10.1016/j.ajpc.2024.100903","DOIUrl":"10.1016/j.ajpc.2024.100903","url":null,"abstract":"<div><h3>Background and aims</h3><div>Elevated lipoprotein(a) [Lp(a)], high-sensitivity C-Reactive Protein (hs-CRP), and total homocysteine (tHcy) are associated with atherosclerotic cardiovascular disease (ASCVD) risk. This study investigated the individual and joint associations of Lp(a), hs-CRP and tHcy with coronary heart disease (CHD) and stroke.</div></div><div><h3>Methods</h3><div>This study was conducted in the Multi-Ethnic Study of Atherosclerosis (MESA) cohort (2000–2017) (CHD analytic <em>N</em> = 6,676; stroke analytic <em>N</em> = 6,674 men and women). Associations between Lp(a) (&lt;50 vs. ≥50 mg/dL), hs-CRP (&lt;2 vs. ≥2 mg/L) and tHcy (&lt;12 vs. ≥12 µmol/L) and CHD and stroke incidence were evaluated individually and jointly using Cox proportional hazards regression.</div></div><div><h3>Results</h3><div>Individually, elevated tHcy was associated with CHD and stroke incidence, Lp(a) with CHD only and hs-CRP with stroke only. In combined analyses, CHD risk was higher when multiple biomarkers were elevated [hs-CRP+Lp(a), hazard ratio (HR)=1.39, 95 % confidence interval (CI): 1.06, 1.82; hs-CRP+ tHcy, HR = 1.34, 95 % CI: 1.02, 1.75; Lp(a)+ tHcy HR = 1.58, 95 % CI: 1.08, 2.30; hs-CRP+Lp(a)+ tHcy HR = 2.02, 95 % CI: 1.26, 3.24]. Stroke risk was elevated when hs-CRP and either Lp(a) (HR = 1.51, 95 % CI: 1.02, 2.23) or tHcy (HR = 2.10, 95 % CI: 1.44, 3.06) was also high, when all three biomarkers were elevated (HR = 2.99, 95 % CI: 1.61, 5.58), or when hs-CRP and tHcy (HR = 1.79, 95 % CI: 1.16, 2.76) were both high.</div></div><div><h3>Conclusions</h3><div>Risk of ASCVD was highest with concomitant elevation of tHcy, hs-CRP and Lp(a). Inclusion of tHcy and consideration of biomarker combination rather than individual biomarker levels may help better identify individuals at greatest risk for ASCVD events.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"21 ","pages":"Article 100903"},"PeriodicalIF":4.3,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11722194/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiopulmonary exercise test with bicycle stress echocardiography for predicting adverse cardiac events in patients with stage A or B heart failure","authors":"Houng-Beom Ahn ,&nbsp;Jiesuck Park ,&nbsp;Hye Jung Choi ,&nbsp;Hong-Mi Choi ,&nbsp;In-Chang Hwang ,&nbsp;Yeonyee E. Yoon ,&nbsp;Goo-Yeong Cho","doi":"10.1016/j.ajpc.2024.100913","DOIUrl":"10.1016/j.ajpc.2024.100913","url":null,"abstract":"<div><h3>Background</h3><div>Given the high prevalence of stage A or B heart failure (HF), comprehensive screening for new-onset HF is cost-prohibitive. Therefore, further risk stratification is warranted to identify at-risk patients. This study aimed to evaluate the prognostic utility of cardiopulmonary exercise test (CPET) with bicycle stress echocardiography (BSE) in patients with stage A or B HF.</div></div><div><h3>Methods</h3><div>Among 687 consecutive patients who underwent CPET-BSE, 410 with stage A or B HF were analyzed. The association between the CPET-BSE parameters and adverse cardiac events (hospitalization for HF or cardiac-related death) was analyzed using the Cox proportional hazard model under univariate and multivariate analyses.</div></div><div><h3>Results</h3><div>After a median 9 years of follow-up, 47 (11.5 %) of the 410 patients had events. In the univariable analysis, age, diuretics, BUN, creatinine, peak oxygen uptake (VO2), ventilatory efficiency (VE/VCO₂), time to VT and peak exercise, left atrial volume index, rest and exercise E/e′, and tricuspid regurgitation velocity demonstrated significant parameters. In multivariate analysis, VE/VCO₂ (hazard ratio [HR] 1.205, 95 % CI 1.095–1.327) and VO₂ at peak exercise (HR 1.164, 95 % CI 1.022–1.325), time to VT (HR 0.993, 95 % CI 0.989–0.997), and exercise E/e′ (HR 1.582, 95 % CI 1.199–2.087) were only independent predictors for events.</div></div><div><h3>Conclusions</h3><div>In patients with stage A or B HF, four parameters of CPET-BSE were good predictors of future development of HF or cardiac death. If patients are unable to perform complete exercise, the time to VT may serve as a sufficiently predictive parameter for clinical events.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"21 ","pages":"Article 100913"},"PeriodicalIF":4.3,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11697780/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ASPC2025_CallForAbstracts_JournalAd_PRINT.pdf","authors":"","doi":"10.1016/S2666-6677(24)00280-0","DOIUrl":"10.1016/S2666-6677(24)00280-0","url":null,"abstract":"","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"20 ","pages":"Article 100911"},"PeriodicalIF":4.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143129287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}